Liraglutide and Semaglutide have become key players in the pharmaceutical and healthcare industry as they are both being used and have been approved not only as an anti-diabetic medication but also as an obesity and weight loss treatment
a 0.4% BMI reduction for the placebo group, according to the efficacy estimand
NICE TA875 specifies that NHS access to semaglutide for weight management is restricted to specialist weight management services (tier 3 or 4) for patients meeting specific criteria
Effectiveness on glycemic control By considering the glycemic control, at the first visit mean HBA1C was of 7.7 1.6% and after 6, 12, and 24 months from the beginning of the treatment was respectively 6.4 0.8%, 6.3 0.6%, and 6.4 1.0%, with a mean percentage reduction of 1.9 1.4%, 1.5 1.9%, and 1.5 1.7% in the IS group (Fig
Rybelsus 7mg is used to improve blood sugar control in adults with type 2 diabetes alongside diet and exercise
Opportunity Costs and Alternative Uses of Resources Responsible decision-making also considers opportunity costs - what alternative uses might the resources devoted to injectable glutathione serve